Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sagimet Biosciences Inc.

3.74
+0.23006.55%
Post-market: 3.780.0400+1.07%18:53 EDT
Volume:281.00K
Turnover:1.04M
Market Cap:120.41M
PE:-2.90
High:3.80
Open:3.55
Low:3.50
Close:3.51
Loading ...

Company Profile

Company Name:
Sagimet Biosciences Inc.
Exchange:
NASDAQ
Establishment Date:
2006
Employees:
9
Office Location:
155 Bovet Road,Suite 303,San Mateo,California,United States
Zip Code:
94402
Fax:
- -
Introduction:
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Directors

Name
Position
David Happel
President, Chief Executive Officer and Director
George Kemble
Executive Chairman of the Board
Beth Seidenberg
Director
Elizabeth Grammer
Director
Gordon Ringold
Director
James F. Young
Director
Jinzi J. Wu
Director
Merdad Parsey
Director
Richard Rodgers
Director

Shareholders

Name
Position
David Happel
President, Chief Executive Officer and Director
Anthony Rimac
Chief Operating Officer
Dennis Hom
Chief Financial Officer
Eduardo Bruno Martins
Chief Medical Officer
Elizabeth Rozek
General Counsel and Chief Compliance Officer